Genomic Surveillance Reveals Hidden Transmission and Rising Drug Resistance in C. difficile

Clostridioides difficile remains the leading cause of healthcare-associated diarrhea and is classified as an urgent antimicrobial resistance threat, but a new review argues that the organism clinicians now face differs substantially from the strain that drove the historical ribotype 027 epidemics. The review is organized around a single question: which parts of the C. difficile transmission and treatment cycle are invisible to the methods currently used to observe them?

The first answer concerns hospital transmission. Whole-genome sequencing consistently identifies genomic links between hospital cases that ward-based contact tracing cannot reconcile. Notably, isolates from asymptomatically colonized patients are linked to subsequent cases as often as isolates from symptomatic patients, in some instances many months after an index encounter. The authors draw on a four-year single-center study from Guangzhou, China, in which one of the review authors participated, alongside comparable cohorts from England, Denmark and Canada.

A second strand of evidence comes from One Health genomics, which places human and non-human compartments within a single transmission network. Sequence type 11 and its ribotype 078 sublineage circulate between livestock and humans at clonal resolution, cryptic clades meet species-level divergence thresholds, and community-associated disease accounts for roughly a third of cases. The review stresses, however, that the direction of transfer between animals and people and the attributable fraction of human disease remain unquantified.

Resistance to first-line therapy now has defined molecular mechanisms. These include plasmid-borne and heme-dependent metronidazole resistance, constitutive vanG expression underlying reduced vancomycin susceptibility, and RNA polymerase substitutions conferring reduced fidaxomicin susceptibility that emerge during treatment. Several of these mechanisms are undetectable under standard laboratory conditions, complicating routine susceptibility testing.

The review also reframes pathogenesis as polymicrobial, describing how enterococci cross-feed leucine and ornithine while depleting arginine as a virulence cue. These strands are integrated with age-stratified vulnerability in older and pediatric patients, the diagnostic challenge of separating true infection from colonization, and the diverging regulatory frameworks that now distinguish donor-derived fecal microbiota transplantation from licensed live biotherapeutic products. Together, the authors contend, these developments define the next generation of diagnostics, therapeutics and vaccines for a pathogen whose transmission and resistance landscape has outpaced conventional surveillance.

Subject of Research: Molecular epidemiology, One Health transmission and antimicrobial resistance mechanisms in Clostridioides difficile infection

Article Title: Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines

Article References: El-Sayed Ahmed, M. A. E.-G., El-Lakany, R. R., Ramadan, M., & Goda, R. M. (2026). Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines. Frontiers in Cellular and Infection Microbiology, 16, Article 1992944. https://doi.org/10.3389/fcimb.2026.1992944

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1992944

Keywords: Clostridioides difficile, whole-genome sequencing, healthcare-associated diarrhea, antimicrobial resistance, One Health, ribotype 078, metronidazole resistance, vancomycin, fidaxomicin, polymicrobial pathogenesis, fecal microbiota transplantation, colonization